Employees: 96
Size Annexon (ANNX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $671M, the 2491st largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.52 on 18 Nov 2026.
Performance Over six months the shares fell 30.2%, against -6.0% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 21 in its peer set.
Short interest Short interest is 15.3% of the free float (30 Oct 2026).
Next results Next results expected around 8 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$3.85M | -$3.69M | -$3.45M | -$3.27M | -$3.31M |
| EBITDA | -$202M | -$213M | -$151M | -$140M | -$142M |
| Net income | -$199M | -$207M | -$138M | -$134M | -$142M |
| Free cash flow | -$190M | -$186M | -$118M | -$121M | -$123M |
| Capital expenditure | $137,000 | $137,000 | $15,000 | $193,000 | $6.53M |
| Total debt | $73.2M | $26.2M | $29.0M | $31.4M | $32.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ANNX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.1% | -2.8% | 7th lowest of 21 |
| 6-month return | -30.2% | -6.0% | 5th lowest of 21 |
| Distance from 52-week high | -51.0% | -28.2% | 6th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Annexon ANNX | United States | $671M | -30% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $672M | -35% | +7% | 8% | 6.7× | 31.9% | +19.8% |
| Philogen PHIL.MI | Italy | $672M | -11% | +295% | 79% | 0.9× | n/a | n/a |
| Youcare Pharmaceutical 688658.SS | China | $674M | -49% | -7% | -13% | 1.7× | n/a | n/a |
| Yabao Pharmaceutical 600351.SS | China | $678M | 0% | -3% | 16% | 1.6× | -8.3% | -2.8% |
| Sun Pharma Advanced Research SPARC.NS | India | $660M | +6% | +3,141% | 84% | 2.5× | n/a | n/a |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -31% | -36% | 36% | 2.5× | n/a | n/a |
| Earth 4985.T | Japan | $687M | +7% | +4% | 4% | 0.5× | -1.6% | -1.8% |
| FDC FDC.NS | India | $653M | +3% | +10% | 14% | 2.4× | 25.2% | +10.3% |
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| Innova Captab INNOVACAP.NS | India | $645M | +20% | +37% | 12% | 3.4× | 27.1% | +31.4% |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | 0.6× | 4.0% | +5.3% |
| Hainan Haiyao 000566.SZ | China | $642M | -18% | -18% | -50% | 10.6× | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $641M | -19% | +23% | 11% | 3.0× | 9.1% | +7.9% |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | 12.8× | 36.3% | +16.2% |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | 16.9× | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $714M | -3% | +16% | 10% | 0.8× | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | 1.6× | n/a | n/a |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | 0.3× | n/a | n/a |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 2.6× | -4.8% | +6.4% |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |